A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the ...
Credit: Getty Images New research is being conducted on factor XI inhibitor therapy as the patent expiration for factor Xa inhibitors nears. Factor XI inhibitor therapy research is being conducted as ...
Andexanet alfa (Andexxa; AstraZeneca), compared with usual care, improves hemostasis in patients who have an intracranial bleed while taking a factor Xa inhibitor, according to top-line results of ...
A selective factor XIa inhibitor could make for an effective anticoagulant with a good safety profile, according to a phase II study in elective knee arthroplasty. Larger doses of oral milvexian ...
Cumulative safety data from three trials testing the reversible direct factor XIa inhibitor asundexian in patients at risk for stroke or recurrent cardiovascular events suggest a better bleeding ...
Acquisition significantly enhances the Company’s pipeline by adding novel assets in acute and chronic anticoagulation settings Company is strategically poised to deliver differentiated therapeutics ...
Please provide your email address to receive an email when new articles are posted on . In patients with nonvalvular atrial fibrillation receiving oral anticoagulants, factor Xa inhibitors appeared ...
Please provide your email address to receive an email when new articles are posted on . In the AXIOMATIC-SSP trial, milvexian, a novel factor XIa inhibitor, was protective against ischemic stroke with ...
PONTE VEDRA, FL / / December 29, 2025 / Every industry has its forgotten corners. In anticoagulation, those corners turned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback